Maarten C. C. M. Hulshof

Maarten C. C. M. Hulshof

Auto-generated profile, based on publicly available information

Maarten C. C. M. Hulshof

Department of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PHP. van Hagen
P. van Hagen
MHM.C.C.M. Hulshof
M.C.C.M. Hulshof
JLJ.J.B. van Lanschot
J.J.B. van Lanschot
ESE.W. Steyerberg
E.W. Steyerberg
Mark I. van Berge HenegouwenMark I. van Berge Henegouwen
Mark I. van Berge Henegouwen
AGA. van der Gaast
A. van der Gaast
The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population.

1 September 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
JSJoel Shapiro
Joel Shapiro
JLJ Jan B van Lanschot
J Jan B van Lanschot
MHMaarten C C M Hulshof
Maarten C C M Hulshof
PHPieter van Hagen
Pieter van Hagen
Mark I. van Berge HenegouwenMark I. van Berge Henegouwen
Mark I. van Berge Henegouwen
AGAte van der Gaast
Ate van der Gaast

20 June 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BEBen M. Eyck
Ben M. Eyck
JLJ. Jan B. van Lanschot
J. Jan B. van Lanschot
MHMaarten C. C. M. Hulshof
Maarten C. C. M. Hulshof
BWBerend J. van der Wilk
Berend J. van der Wilk
JSJoel Shapiro
Joel Shapiro
FGfor the CROSS Study Group
for the CROSS Study Group
PURPOSE: Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer. We aimed to assess long-term outcome of this regimen. METHODS: From 2004 through 2008, we randomly assigned 366 patients to either five weekly cycles of carboplatin and paclitaxel with concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week) followed by surgery, or surgery alone. Follow-up data were collected through 2018. Cox regression analyses were performed to compare overall survival, cause-specific survival, and risks of locoregional and distant relapse. The effect of neoadjuvant chemoradiotherapy beyond 5 years of follow-up was tested with time-dependent Cox regression and landmark analyses. RESULTS: The median follow-up was 147 months (interquartile range, 134-157). Patients receiving neoadjuvant chemoradiotherapy had better overall survival (hazard ratio [HR], 0.70; 95% CI, 0.55 to 0.89). The effect of neoadjuvant chemoradiotherapy on overall survival was not time-dependent ( P value for interaction, P = .73), and landmark analyses suggested a stable effect on overall survival up to 10 years of follow-up. The absolute 10-year overall survival benefit was 13% (38% v 25%). Neoadjuvant chemoradiotherapy reduced risk of death from esophageal cancer (HR, 0.60; 95% CI, 0.46 to 0.80). Death from other causes was similar between study arms (HR, 1.17; 95% CI, 0.68 to 1.99). Although a clear effect on isolated locoregional (HR, 0.40; 95% CI, 0.21 to 0.72) and synchronous locoregional plus distant relapse (HR, 0.43; 95% CI, 0.26 to 0.72) persisted, isolated distant relapse was comparable (HR, 0.76; 95% CI, 0.52 to 1.13). CONCLUSION: The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.

1 March 1995 in The Lancet
Verified
Journal Article
Closed access
JOJ. Overgaard
J. Overgaard
SBSoren Bentzen
Soren Bentzen
DGD. Gonzalez Gonzalez
D. Gonzalez Gonzalez
MHM.C.C.M. Hulshof
M.C.C.M. Hulshof
GAG. Arcangeli
G. Arcangeli
OMO. Mella
O. Mella

10 February 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VOVera Oppedijk
Vera Oppedijk
AGAte van der Gaast
Ate van der Gaast
JLJan J.B. van Lanschot
Jan J.B. van Lanschot
PHPieter van Hagen
Pieter van Hagen
RORob van Os
Rob van Os
MHMaarten C.C.M. Hulshof
Maarten C.C.M. Hulshof
Purpose: To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone. Patients and Methods: Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin. Results: Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75%). Of the 374 patients who underwent resection, 86% were allocated to surgery and 92% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58% versus 35% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35% v 29%; P = .025). LRR occurred in 5% within the target volume, in 2% in the margins, and in 6% outside the radiation target volume. In 1%, the exact site in relation to the target volume was unclear. Only 1% had an isolated infield recurrence after CRT plus surgery. Conclusion: Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5%, mostly combined with outfield failures.

1 January 2009 in International Journal of Hyperthermia
Verified
Journal Article
Closed access
PDF file
Johannes Hans CrezeeJohannes Hans Crezee
Johannes Hans Crezee
PHP.M.A. Van Haaren
P.M.A. Van Haaren
HWH. Westendorp
H. Westendorp
MGM. De Greef
M. De Greef
H.P. KokH.P. Kok
H.P. Kok
ABA. Bel
A. Bel
Background: The aim of this study is preclinical evaluation of our newly developed regional hyperthermia system providing 3-D SAR control: the AMC-8 phased array consisting of two rings, each with four 70 MHz waveguides. It was designed to achieve higher tumour temperatures and improve the clinical effectiveness of locoregional hyperthermia. Methods: The performance of the AMC-8 system was evaluated with simulations and measurements aiming at heating a centrally located target region in rectangular (30 × 30 × 110 cm) and elliptical (36 × 24 × 80 cm) homogeneous tissue equivalent phantoms. Three properties were evaluated and compared to its predecessor, the 2-D AMC-4 single ring four waveguide array: (1) spatial control and (2) size of the SAR focus, (3) the ratio between maximum SAR outside the target region and SAR in the focus. Distance and phase difference between the two rings were varied. Results: (1) Phase steering provides 3-D SAR control for the AMC-8 system. (2) The SAR focus is more elongated compared to the AMC-4 system, yielding a lower SAR level in the focus when using the same total power. This is counter-balanced by (3) a superficial SAR deposition which is half of that in the AMC-4 system, yielding a more favourable ratio between normal tissue and target SAR and allowing higher total power and up to 30% more SAR in the focus for 3 cm ring distance. Conclusion: The AMC-8 system is capable of 3-D SAR control and its SAR distribution is more favourable than for the 2-D AMC-4 system. This result promises improvement in clinical tumour temperatures.